When assessing acceptance rates by hormone receptor status, active steps towards the offered strategy for ovarian function preservation with GnRHa administration were perused by 45 out of 49 (91.8%) women with hormone receptor-positive breast cancer and by 13 out of 15 (86.7%) with hormone receptor-negative disease (Figure 4). The gene discussed is NR4A1; the disease is breast carcinoma.